Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage [2]

British Journal of Anaesthesia

Volumn 98, Issue 5, 2007, Pages 690-691

  Bowles, K M ^a   Park, Gilbert R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7; RECOMBINANT PROTEIN;

BLEEDING; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG RESPONSE; HUMAN; LETTER; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; SCORING SYSTEM; THROMBOSIS; ACIDOSIS; CLINICAL TRIAL; HEMORRHAGIC SHOCK; HEMOSTASIS; HIGH RISK PATIENT; MORTALITY; PREDICTION; SURVIVAL; TREATMENT OUTCOME; EVIDENCE BASED MEDICINE; HOSPITALIZATION; NOTE; PATIENT SELECTION; PROGNOSIS;

EVIDENCE-BASED MEDICINE; FACTOR VII; HEMORRHAGE; HUMANS; PATIENT SELECTION; PROGNOSIS; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX;

EID: 34250302666     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aem076     Document Type: Letter

References (9)

1. Bowles KM, Callaghan CJ, Taylor AL, et al. Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage. Br J Anaesth 2006; 97: 476-81
2. Biss TT, Hanley JP. Recombinant activated factor VII (rFVIIa/NovoSeven) in intractable haemorrhage: Use of clinical scoring system to predict outcome. Vox Sang 2006; 90: 45-52
3. Pugh RJ, Wenstone R, Goh AN. Off-label use of recombinant activated factor VII (rFVIIa) for life-threatening haemorrhage. Intensive Care Med 2006; 32: S61
4. Nfor TK, Walsh TS, Prescott RJ. The impact of organ failures and their relationship with outcome in intensive care: Analysis of a prospective multicentre database of adult admissions. Anaesthesia 2006; 61 731-8
5. Mayo A, Misgav M, Kluger Y, et al. Recombinant activated factor VII (NovoSeven): Addition to replacement therapy in acute, uncontrolled and life-threatening bleeding. Vox Sang 2004; 87: 34-40
6. Stein DM, Dutton RP, O'Connor J, Alexander M, Scalea TM. Determinants of futility of administration of recombinant factor VIIa in trauma. J Trauma 2005; 59: 609-15
7. Meng ZH, Wolberg AS, Monroe DM, Hoffman M. The effects of temperature and pH on the activity of factor VIIa: Implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003; 55: 886-91
8. Martinowitz U, Michaelson M, The Israeli Multidisciplinary rFVIIa Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: A report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 2005; 3 640-8
9. MacLaren R, Weber LA, Brake H, Gardner MA, Tanzi M. A multicenter assessment of recombinant factor VIIa off-label usage: Clinical experiences and associated outcomes. Transfusion 2005; 45: 1434-42